Early study suggests major advance in cholesterol control and heart disease prevention

Scientists have unveiled a promising experimental therapy that could significantly reduce “bad” cholesterol levels, potentially marking a major step forward in the treatment of heart disease risk factors.

Researchers from the University of Barcelona and the University of Oregon have developed a DNA-based approach that targets a key protein linked to high levels of low-density lipoprotein (LDL), commonly known as bad cholesterol.

LDL cholesterol is a fatty substance that can accumulate in artery walls, restricting blood flow and increasing the risk of serious conditions such as heart attacks and strokes.

Over time, elevated levels can contribute to hypercholesterolemia, a condition strongly associated with cardiovascular disease.

The new treatment works by blocking a protein called PCSK9, which plays a major role in maintaining high LDL levels in the bloodstream.

When PCSK9 is active, it prevents the body from efficiently removing excess cholesterol.

Researchers designed specialized DNA-based molecules known as polypurine hairpins to suppress the production of this protein.

By inhibiting PCSK9, the therapy allows cells to absorb more cholesterol, reducing the amount circulating in the blood.

In laboratory studies involving human liver cells and genetically modified mice, the experimental treatment showed the ability to lower cholesterol levels by nearly 50 percent, according to early findings published in the journal Biochemical Pharmacology.

If further research confirms these results in human trials, scientists say the approach could offer a more targeted and potentially safer alternative to current cholesterol-lowering medications, which are widely used but can sometimes produce side effects.

Experts involved in the study suggest the findings could open the door to new strategies for preventing atherosclerosis, a condition caused by plaque buildup in the arteries that remains one of the leading contributors to cardiovascular disease worldwide.

While the research is still in its early stages, the results are being viewed as a significant development in the ongoing effort to improve long-term heart health through more precise and innovative medical treatments.